Permira mulls €3–4bn sale of CNS-focused pharma group Neuraxpharm
Permira is exploring a potential exit from Neuraxpharm, the European pharmaceutical group specialising in central nervous system (CNS) disorders, in a deal that could value the company at €3bn–€4bn ($3.5bn–$4.2bn), according to a report by Bloomberg.